Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TN-TC11G (THC+CBD) With Temozolomide and Radiotherapy in Newly-diagnosed Glioblastoma
NCT03529448Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Neurooncología
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Tilray FS Oral Solution in glioblastoma (GBM), sponsored by Grupo Español de Investigación en Neurooncología. Started Aug 2023; status: completed.
02
Drugs
Tilray FS Oral Solution
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03529448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03529448.